We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
CV Therapeutics has announced that an analysis of unblinded data from the MERLIN TIMI-36 study shows there was no adverse trend in death or arrhythmias in patients on ranolazine.
Sosei announced that it has begun a Phase I comparative pharmacokinetic study of AD 923, its novel sublingual fentanyl spray for the treatment of cancer breakthrough pain, under an investigational new drug application.
CollaGenex Pharmaceuticals has announced the results of a Phase II dose-finding study designed to evaluate the safety and determine the therapeutic range of incyclinide for the treatment of acne.
Map Pharmaceuticals announced that its Tempo Migraine drug candidate met the primary endpoints in a Phase II clinical program consisting of two separate trials.
Myriad Genetics presented additional results from its Phase II follow-on study of Flurizan in patients with mild Alzheimer's disease at the annual meeting of the American Association for Geriatric Psychiatry.
Human Genome Sciences (HGS) has initiated dosing in ACHIEVE 2/3, a Phase III clinical trial of Albuferon in combination with ribavirin in treatment-naive patients with chronic hepatitis C genotypes 2 and 3.